Axonics, Inc. (NASDAQ:AXNX) COO Rinda Sama sold 1,362 shares of the business’s stock in a transaction that occurred on Thursday, June 10th. The stock was sold at an average price of $60.02, for a total value of $81,747.24. Following the transaction, the chief operating officer now owns 29,898 shares in the company, valued at $1,794,477.96. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Rinda Sama also recently made the following trade(s):
- On Tuesday, June 8th, Rinda Sama sold 1,000 shares of Axonics stock. The stock was sold at an average price of $60.23, for a total value of $60,230.00.
- On Tuesday, May 11th, Rinda Sama sold 25,000 shares of Axonics stock. The stock was sold at an average price of $53.35, for a total value of $1,333,750.00.
- On Thursday, April 15th, Rinda Sama sold 73,848 shares of Axonics stock. The stock was sold at an average price of $59.06, for a total value of $4,361,462.88.
NASDAQ AXNX opened at $59.90 on Friday. The company has a current ratio of 9.50, a quick ratio of 6.53 and a debt-to-equity ratio of 0.23. The stock has a market capitalization of $2.51 billion, a price-to-earnings ratio of -36.52 and a beta of 0.07. The company has a 50 day simple moving average of $57.97. Axonics, Inc. has a one year low of $32.15 and a one year high of $64.36.
Several brokerages have recently weighed in on AXNX. Piper Sandler reissued an “overweight” rating and set a $75.00 price target (up previously from $70.00) on shares of Axonics in a research report on Friday, May 7th. Morgan Stanley increased their price target on shares of Axonics from $58.00 to $62.00 and gave the company an “overweight” rating in a research note on Friday, May 7th. Needham & Company LLC upped their price objective on Axonics from $71.00 to $72.00 and gave the company a “buy” rating in a report on Friday, May 7th. Finally, Zacks Investment Research cut Axonics from a “hold” rating to a “sell” rating in a research note on Tuesday, May 11th. One analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $66.11.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Eaton Vance Management acquired a new stake in Axonics in the 1st quarter valued at about $30,000. US Bancorp DE raised its holdings in Axonics by 106.5% in the fourth quarter. US Bancorp DE now owns 735 shares of the company’s stock valued at $37,000 after acquiring an additional 379 shares in the last quarter. Lazard Asset Management LLC purchased a new position in Axonics in the first quarter worth approximately $46,000. Nisa Investment Advisors LLC grew its holdings in Axonics by 22.2% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,100 shares of the company’s stock worth $55,000 after acquiring an additional 200 shares in the last quarter. Finally, Rockefeller Capital Management L.P. purchased a new stake in shares of Axonics in the 1st quarter valued at approximately $80,000. Institutional investors own 89.00% of the company’s stock.
Axonics Company Profile
Axonics, Inc, a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention.
Further Reading: P/E Growth (PEG)
Receive News & Ratings for Axonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axonics and related companies with MarketBeat.com's FREE daily email newsletter.